Neurological Disorders

The central nervous system (CNS) has a limited capacity to spontaneously regenerate following traumatic injury or disease, requiring innovative strategies to promote tissue and functional repair. Tissue regeneration strategies, like cell and/or drug delivery, have demonstrated promising leads to experimental animal models, but are difficult to translate clinically. The efficacy of cell therapy, which involves somatic cell transplantation into the CNS to exchange damaged tissue, has been limited thanks to low cell survival and integration upon transplantation, while delivery of therapeutic molecules to the CNS using conventional methods, like oral and intravenous administration, are limited by diffusion across the blood– brain/spinal cord-barrier. The use of biomaterials to market graft survival and integration also as localized and sustained delivery of biologics to CNS injury sites is actively being pursued. This review will highlight recent advances using biomaterials as cell- and drug-delivery vehicles for CNS repair

Current diagnosis of Alzheimer's disease relies largely on documenting mental decline, at which point, Alzheimer's has already caused severe brain damage. Researchers hope to get a simple and accurate thanks to detect Alzheimer's before these devastating symptoms begin. Experts believe that biomarkers (short for "biological markers") offer one among the foremost promising paths. A biomarker are some things which will be measured to accurately and reliably indicate the presence of disease, like fasting blood sugar (blood sugar) level, which indicates the presence of diabetes if it's 126 mg/dL or higher.